Clinical trial · no report yet · Phase 2
CHIMERA
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
- NCT06155279 ↗
- Active, not recruiting
- Istituto Oncologico Veneto IRCCS
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Pleural Mesothelioma
- Interventions
- Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
- Arms
- Single arm · Experimental
- Enrollment
- 41
- Primary outcomes
- Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR)
- Sponsor
- Istituto Oncologico Veneto IRCCS with MSD Italia S.r.l.
- Start
- Nov 6, 2024
- Primary completion
- Dec 22, 2025
- Results posted
- No
- Registry record
- NCT06155279 · updated Jan 13, 2026